fda ghk-cu immunogenicity risk adds non-injectable back to Category 1. FDA Thursday re-added 🧬 The FDA just made

Dramatic gastric emptying delay: Most powerful effect of amylin Slows stomach emptying significantly Food stays in stomach 2-3x longer Extended fullness sensation Reduced appetite through mechanical fullness Limits food intake naturally 2

Disentangling the relationship between anxiety and AUD will clarify our understanding of the risk factors of each disorder and inform treatments

Animal Toxicology Studies Animal toxicology studies tested doses from 0.0027 mg/lb to 9.1 mg/lb via intraperitoneal, intramuscular, intravenous, and oral routes for up to 6 weeks, finding: No acute toxic or lethal dose No gross or histologic toxicity in major organs No hepatotoxicity or nephrotoxicity Negative Ames test (no mutagenicity) Negative chromosomal aberration tests (no genotoxicity) No teratogenicity in rat pregnancy studies No local injection site irritation The LD1 (minimum lethal dose) could not be achieved despite aggressive testing

The findings suggest that specimens exposed to the GHK-Cu peptide complex may exhibit better-supported tissue organization and repair-associated characteristics relative to comparator groups